Bullish
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression
Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 study of vamorolone in healthy volunteers. The study demonstrated ...